Journal
VACCINE
Volume 40, Issue 26, Pages 3506-3510Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2022.02.040
Keywords
Respiratory syncytial virus; Monoclonal antibody; Passive immunization
Categories
Funding
- Bill & Melinda Gates Foundation [OPP1114766]
- Bill and Melinda Gates Foundation [OPP1114766] Funding Source: Bill and Melinda Gates Foundation
Ask authors/readers for more resources
This article summarizes the preferred product characteristics for monoclonal antibodies to prevent severe RSV disease in infants, as published by the World Health Organization. It discusses key considerations for future access and use of these preventive antibodies.
World Health Organization (WHO) preferred product characteristics describe preferences for product attributes that would help optimize value and use to address global public health needs, with a particular focus on low- and middle-income countries. Having previously published preferred product characteristics for both maternal and paediatric respiratory syncytial virus (RSV) vaccines, WHO recently published preferred product characteristics for monoclonal antibodies to prevent severe RSV disease in infants. This article summarizes the key attributes from the preferred product characteristics and discusses key considerations for future access and use of preventive RSV monoclonal antibodies. (C) 2022 World Health Organization. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available